THOSE U WANT TO TRADE ON MY CALL FOR THE FIRST TIME. DO CHECK MY PAST CALL/PERFORMANCE FIRST THEN PUT UR MONEY ON MY CALLS.
CALLS AND NEWS ARE FROM VARIOUS SOURCES (FII'S,DII'S,Promoters & Others)

Thursday, February 19, 2015

Cipla Limited

Cipla Limited (NSE CODE: CIPLA)
Current Market price is Rs.677.00

Investment Idea
Buy around Rs.677.00x120 shares with stoploss Rs.646.00
1st Target: Rs.754.00
2nd Target: Rs.795.00
3rd Target: Rs.836.00

Shareholding Pattern
Promoters 36.80%
Mutual Funds/UTI 4.21%
FII/Banks 31.09%
 Others 27.89%

Price Trend
YTD  8.09%
1 Week  2.18%
1 Month  2.70%
1 Year  82.22%
3 Years  110.36%

Company Profile
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.
web site : http://www.cipla.com/
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

DISCLAIMER :

The information and views contained in this site are believed to be reliable , but no responsibility (or liability ) is accepted for errors of fact or opinion . The writer may be trading in or may have positions in the Equity,F&O And Commodity mentioned in their article .We do not accept any liability arising out of the use of the above information / article. Reproduction in whole or in part without written permission is prohibited.